FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
KDIGO provided recommendations on SGLT2 inhibitors and …
WEBMay 12, 2023 · Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two …
WEBFeb 1, 2023 · Results from two new trials and two new meta-analyses conclusively demonstrate the cardio-protective and kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors across the breadth of heart failure and chronic kidney disease populations studied, with absolute benefits convincingly outweighing the …
SGLT2 inhibitors and GLP-1 receptor agonists: established and …
WEBSGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as glucose lowering therapies, with additional benefits of weight loss and blood pressure reduction.
SGLT2 inhibitors as the bedrock of therapy for heart failure
WEBSep 3, 2022 · Despite the differences in patient populations and study designs, the evidence is strikingly consistent and resoundingly clear—SGLT2 inhibitors are the bedrock of therapy for heart failure regardless of ejection fraction or care setting.
SGLT2 inhibitors: role in protective reprogramming of cardiac
WEBJan 6, 2023 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by direct action on the failing heart that is independent of changes in renal tubular function.
FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and ... - Pfizer
WEBDec 22, 2017 · Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATRO™ (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tabl...
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · SGLT2 inhibitors reduce the risk of cardiovascular death and heart failure hospitalization among people with type 2 diabetes mellitus and have beneficial effects on key heart failure outcomes...
- Some results have been removed